Group 1 - Biophytis SA has published the Phase 2 clinical trial results for its lead drug candidate BIO101 in the Journal of Cachexia, Sarcopenia and Muscle, marking a significant milestone in the treatment of sarcopenia [1][3] - The company is progressing towards regulatory approvals for its Phase 3 trial in sarcopenia and is in discussions with a major international pharmaceutical company in China and other partners in Asia [2] - Sarcopenia currently affects between 121 and 194 million people globally, with no existing therapeutic solutions, positioning Biophytis as a leader in this indication with BIO101 [5] Group 2 - BIO101, at a dosage of 350mg bid, has shown a clinically meaningful improvement in the 400-meter walk test, which is the primary endpoint of the study [4] - The safety profile of BIO101 is excellent, with no serious adverse events related to the product reported at any dosage [4] - The treatment effect of BIO101 is notably significant in high-risk populations, particularly among slow walkers and those with sarcopenic obesity [4]
Biophytis Revolutionizes Sarcopenia